keyword
MENU ▼
Read by QxMD icon Read
search

direct acting antiviral

keyword
https://www.readbyqxmd.com/read/29454794/hcv-genotype-6a-escape-from-and-resistance-to-velpatasvir-pibrentasvir-and-sofosbuvir-in-robust-infectious-cell-culture-models
#1
Long V Pham, Santseharay Ramirez, Judith M Gottwein, Ulrik Fahnøe, Yi-Ping Li, Jannie Pedersen, Jens Bukh
BACKGROUND & AIMS: Chronic liver diseases caused by hepatitis C virus (HCV) genotype 6 are prevalent in Asia, and millions of people require treatment with direct-acting antiviral regimens, such as NS5A inhibitor velpatasvir combined with the NS5B polymerase inhibitor sofosbuvir. We developed infectious cell culture models of HCV genotype 6a infection to study the effects of these inhibitors and the development of resistance. METHODS: The consensus sequences of prototype strains HK2 (MG717925) and HK6a (MG717928), originating from serum of patients with chronic HCV infection, were determined by Sanger sequencing of genomes amplified by reverse transcription-PCR...
February 15, 2018: Gastroenterology
https://www.readbyqxmd.com/read/29453610/hepatitis-c-cure-is-associated-with-decreased-healthcare-costs-in-cirrhotics-in-retrospective-veterans-affairs-cohort
#2
Marissa M Maier, Xiao-Hua Zhou, Michael Chapko, Steven L Leipertz, Xuan Wang, Lauren A Beste
BACKGROUND: Approximately 233,898 individuals in the Veterans Affairs healthcare network are hepatitis C virus (HCV)-infected, making the Veterans Affairs the single largest provider of HCV care in the USA. Direct-acting antiviral treatment regimens for HCV offer high cure rates. However, these medications pose an enormous financial burden, and whether HCV cure is associated with decreased healthcare costs is poorly defined. AIMS: To measure downstream healthcare costs in a national population of HCV-infected patients up to 9 years post-HCV antiviral treatment, to compare downstream healthcare costs between cured and uncured patients, and to assess impact of cirrhosis status on cost differences...
February 16, 2018: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/29451518/-access-to-hepatitis-c-treatment-a-lesson-for-the-future
#3
Lucia Craxì
The new generation of direct acting antivirals (DAA) for the treatment of chronic hepatitis C virus infection has revolutionized the previous scenario and has put the institutions under test because of the high cost of therapies. An analysis of what has happened over the last three years, especially in Italy, helps us understand how price negotiation has been managed, and what criteria were chosen at first to allow limited access on the basis of the need of patient care. This allows to focus on some important issues and to identify the challenges ahead in the near future...
January 2018: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/29451090/study-of-changes-in-lipid-profile-and-insulin-resistance-in-egyptian-patients-with-chronic-hepatitis-c-genotype-4-in-the-era-of-daas
#4
Ghada El Sagheer, Elwy Soliman, Asmaa Ahmad, Lamiaa Hamdy
Chronic hepatitis C virus (HCV) infection is associated with altered metabolism, including dyslipidemia and insulin resistance. These contribute to disease progression and influences the response to therapy. To investigate the relationships of new direct-acting antiviral drugs, simeprevir/sofosbuvir, with lipid profile and insulin resistance (IR). Eighty chronic hepatitis C genotype 4 patients were included; they were divided into four groups according to the severity of fibrosis as detected by fibroscan. Forty healthy persons volunteered as a control group...
December 2018: Libyan Journal of Medicine
https://www.readbyqxmd.com/read/29450210/sofosbuvir-based-direct-acting-antiviral-therapies-for-hcv-in-people-receiving-opioid-substitution-therapy-an-analysis-of-phase-3-studies
#5
Jason Grebely, Jordan J Feld, David Wyles, Mark Sulkowski, Liyun Ni, Joe Llewellyn, Heshaam M Mir, Nika Sajed, Luisa M Stamm, Robert H Hyland, John McNally, Diana M Brainard, Ira Jacobson, Stefan Zeuzem, Marc Bourlière, Graham Foster, Nezam Afdhal, Gregory J Dore
Background: Hepatitis C virus (HCV) direct-acting antiviral therapy is effective among people receiving opioid substitution therapy (OST), but studies are limited by small numbers of nongenotype 1 (GT1) patients. The aim of this study was to evaluate the treatment completion, adherence, SVR12, and safety of sofosbuvir-based therapies in HCV patients receiving and not receiving OST. Methods: Ten phase 3 studies of sofosbuvir-based regimens included ION (ledipasvir/sofosbuvir ± ribavirin for 8, 12, or 24 weeks in GT1), ASTRAL (sofosbuvir/velpatasvir for 12 weeks in GT1-6), and POLARIS (sofosbuvir/velpatasvir and sofosbuvir/velpatasvir/voxilaprevir in GT1-6)...
February 2018: Open Forum Infectious Diseases
https://www.readbyqxmd.com/read/29446143/editorial-are-additional-tests-needed-to-predict-sustained-virologic-response-in-hepatitis-c-treated-with-interferon-free-direct-acting-antiviral-combinations
#6
EDITORIAL
P Ferenci
No abstract text is available yet for this article.
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29446133/editorial-are-additional-tests-needed-to-predict-sustained-virologic-response-in-hepatitis-c-treated-with-interferon-free-direct-acting-antiviral-combinations-authors-reply
#7
EDITORIAL
S Fourati, J-M Pawlotsky
No abstract text is available yet for this article.
March 2018: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/29445911/high-prevalence-of-hcv-gt4-related-tsh-abnormality-among-13402-egyptian-patients-treated-with-direct-acting-antiviral-therapy
#8
Rasha Eletreby, Mohamed Said, Zeinab Abdellatif, Yasmin Saad, Magdy ElSerafy, Hosam Dabes, Kadry ElSaeed, Yehia El-Shazly, Wahid Doss
BACKGROUND: HCV is associated with several extra hepatic diseases including thyroid dysfunction. This study aims at evaluating prevalence of thyroid dysfunction and its possible predictors in a large cohort of HCV GT4-infected patients, and the role of thyroid dysfunction as a predictor of response in the setting of direct acting antivirals (DAAs). METHODS: Patients registered on the web-based registry system to receive therapy for chronic HCV in Beheira governorate viral hepatitis specialized treatment center affiliated to the National committee for control of viral hepatitis (NCCVH), Ministry of health, Egypt in the period from January 2015 to October 2016...
February 14, 2018: Hepatology International
https://www.readbyqxmd.com/read/29445310/training-in-emerging-advances-in-chronic-hepatitis-c-infection-in-pakistan-the-teach-pak-project
#9
Faisal W Ismail, Shahab Abid, Minaz Mawani, Wasim Jafri, Saeed S Hamid
Purpose: Viral hepatitis B and C represent the primary health challenge confronting Asia and Pakistan. With direct-acting antiviral therapy for hepatitis C, patients will be treated by general physicians (GPs) and will need training through continuing medical education (CME). Blended learning is a combination of didactic teaching with online, self-paced learning, and it has not been evaluated as a CME tool for general physicians. We aimed to compare the change in physician's knowledge about chronic viral hepatitis following a blended learning educational program...
2018: Advances in Medical Education and Practice
https://www.readbyqxmd.com/read/29444493/modulators-of-innate-immunity-as-novel-therapeutics-for-treatment-of-chronic-hepatitis-b
#10
REVIEW
Aleksei Suslov, Stefan Wieland, Stephan Menne
The first line defense mechanisms against viral infection are mediated by the innate immune system. Viral components are detected by infected cells and/or innate immune cells that express different sensory receptors. They in turn mediate induction of direct antiviral mechanisms and further modulation of innate and adaptive immune responses. For evading the innate system, most viruses have evolved efficient mechanisms to block sensing and/or antiviral functions of the innate response. Interestingly, hepatitis B virus (HBV) seems to act like a stealth virus that escapes cell intrinsic antiviral mechanisms through avoiding recognition by the innate system rather than blocking its effector functions...
February 11, 2018: Current Opinion in Virology
https://www.readbyqxmd.com/read/29443655/is-interferon-based-treatment-of-viral-hepatitis-c-genotype-3-infection-still-of-value-in-the-era-of-direct-acting-antivirals
#11
Dorota Zarębska-Michaluk, Robert Flisiak, Jerzy Jaroszewicz, Ewa Janczewska, Agnieszka Czauż-Andrzejuk, Hanna Berak, Andrzej Horban, Agnieszka Staniaszek, Andrzej Gietka, Magdalena Tudrujek, Krzysztof Tomasiewicz, Dorota Dybowska, Waldemar Halota, Anna Piekarska, Marek Sitko, Aleksander Garlicki, Iwona Orłowska, Krzysztof Simon, Teresa Belica-Wdowik, Barbara Baka-Ćwierz, Włodzimierz Mazur, Jolanta Białkowska, Łukasz Socha, Marta Wawrzynowicz-Syczewska, Łukasz Laurans, Zbigniew Deroń, Beata Lorenc, Beata Dobracka, Olga Tronina, Małgorzata Pawłowska
The aim of the study is to analyze treatments available for patients infected with genotype (G) 3 hepatitis C virus (HCV) in Poland at the beginning of the interferon (IFN)-free era and evaluate the efficacy and safety of different therapeutic options administered in a real-world setting. We analyzed data of 198 patients who started antiviral therapy after July 1, 2015, and completed it before December 31, 2016; 57.6% of them had liver cirrhosis and 46% were treatment experienced. Fifty percent of patients were assigned to sofosbuvir (SOF)+pegylated IFN alfa (PegIFNa)+ribavirin (RBV), 9% to PegIFNa+RBV, 36% received SOF+RBV, and 5% SOF+daclatasvir (DCV)±RBV...
February 2018: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29439720/plant-derived-antivirals-against-hepatitis-c-virus-infection
#12
REVIEW
Ana Carolina Gomes Jardim, Jacqueline Farinha Shimizu, Paula Rahal, Mark Harris
Hepatitis C virus (HCV) infection is a worldwide public health burden and it is estimated that 185 million people are or have previously been infected worldwide. There is no effective vaccine for prevention of HCV infection; however, a number of drugs are available for the treatment of infection. The availability of direct-acting antivirals (DAAs) has dramatically improved therapeutic options for HCV genotype 1. However, the high costs and potential for development of resistance presented by existing treatment demonstrate the need for the development of more efficient new antivirals, or combination of therapies that target different stages of the viral lifecycle...
February 13, 2018: Virology Journal
https://www.readbyqxmd.com/read/29439266/effect-of-the-opioid-crisis-on-the-donor-pool-for-kidney-transplantation-an-analysis-of-national-kidney-deceased-donor-trends-from-2010-2016
#13
Donald F Chute, Meghan E Sise
BACKGROUND: The opioid crisis has led to a dramatic increase in the number of drug overdose deaths in the United States. Little is known about the effect of the opioid crisis on the kidney transplant donor pool, particularly on hepatitis C virus (HCV)-infected donors. METHODS: This is a retrospective analysis of the data from the Organ Procurement and Transplantation Network from 2010 to 2016. We determined the changes in characteristics of kidney transplant donors and evaluated which changes may be directly related to the opioid crisis...
February 13, 2018: American Journal of Nephrology
https://www.readbyqxmd.com/read/29438397/capacity-of-non-invasive-hepatic-fibrosis-algorithms-to-replace-transient-elastography-to-exclude-cirrhosis-in-people-with-hepatitis-c-virus-infection-a-multi-centre-observational-study
#14
Melissa Louise Kelly, Stephen M Riordan, Rohan Bopage, Andrew R Lloyd, Jeffrey John Post
INTRODUCTION: Achievement of the 2030 World Health Organisation (WHO) global hepatitis C virus (HCV) elimination targets will be underpinned by scale-up of testing and use of direct-acting antiviral treatments. In Australia, despite publically-funded testing and treatment, less than 15% of patients were treated in the first year of treatment access, highlighting the need for greater efficiency of health service delivery. To this end, non-invasive fibrosis algorithms were examined to reduce reliance on transient elastography (TE) which is currently utilised for the assessment of cirrhosis in most Australian clinical settings...
2018: PloS One
https://www.readbyqxmd.com/read/29438195/incidence-of-new-hepatitis-c-virus-infection-is-still-increasing-in-french-msm-living-with-hiv
#15
Pierre Pradat, Thomas Huleux, François Raffi, Pierre Delobel, Marc-Antoine Valantin, Isabelle Poizot-Martin, Pascal Pugliese, Jacques Reynes, David Rey, Bruno Hoen, André Cabie, Firouzé Bani-Sadr, Antoine Cheret, Claudine Duvivier, Christine Jacomet, Anne Fresard, Laurent Hustache-Mathieu, Laurent Cotte
OBJECTIVE: High hepatitis C virus (HCV) treatment uptake combined with effective direct-acting antiviral-based regimens resulted in a dramatic decline of HCV infection in French people living with HIV (PLWH). We assessed the yearly incidence of new HCV infection in PLWH enrolled in the large French Dat'AIDS cohort from 2012 to 2016 with a specific focus on MSM. METHODS: The incidence of new HCV infection was determined yearly in HCV-negative PLWH with serological follow-up during 2012-2016...
February 12, 2018: AIDS
https://www.readbyqxmd.com/read/29433300/treatment-rate-for-hcv-in-the-direct-acting-antivirals-era-in-hiv-co-infected-patients-data-from-an-italian-cohort
#16
Gianluca Cuomo, Cinzia Puzzolante, Claudia Lazzaretti, Giovanni Guaraldi, Vanni Borghi, Cristina Mussini
BACKGROUND: New Direct Antiviral Agents (DAA) are now effective in HCV infection; persons living with HIV (PLWH) were undertreated. Aim of this study was to describe the management of HCV treatment in a HIV/HCV cohort during a 16 years period. METHODS: An electronic review of all HIV patients with > 1 clinic check from the year 2000 was made. De- mographic, virologic and treatment data were collected. RESULTS: From 2000 to 2015 a total of 2352 PLWH were enrolled; 776 (33%) resulted positive at HCV anti- bodies, and were mostly genotype 1 and 3...
January 31, 2018: Minerva Medica
https://www.readbyqxmd.com/read/29432921/complete-response-of-diffuse-large-b-cell-lymphoma-after-direct-acting-antiviral-therapy-for-hepatitis-c-virus
#17
Therese Bittermann, Ethan Weinberg
No abstract text is available yet for this article.
February 9, 2018: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/29432255/solid-organ-transplantation-of-viral-hepatitis-c-positive-donor-organs-into-viral-hepatitis-c-negative-recipients
#18
AnnMarie Liapakis, Richard N Formica, Josh Levitsky
PURPOSE OF REVIEW: Strategies are needed to reduce waitlist mortality and increase transplantation rates. Advances in hepatitis C therapy has allowed the transplant community to look toward utilization of grafts from hepatitis C viremic donors to expand the organ pool. Use of such grafts for hepatitis C-negative patients is being evaluated and debated, and early trial data are emerging. RECENT FINDINGS: Both hepatitis C antibody-positive/nucleic acid test-negative and viremic donors are currently underutilized...
February 9, 2018: Current Opinion in Organ Transplantation
https://www.readbyqxmd.com/read/29430226/a-hepatitis-c-virus-associated-chronic-hepatitis-patient-developing-various-adverse-events-including-severe-gingivitis-gingival-bleeding-and-inflammation-of-genital-vulva-during-the-course-of-antiviral-therapy-with-elbasvir-grazoprevir
#19
Kazuo Tarao, Akira Sato
Oral direct-acting antivirals comprise the main therapy for hepatitis C virus (HCV)-associated liver disease in Japan. Daclatasvir/asunaprevir is the primary agent and sofosbuvir/ledipasvir is the secondary agent for HCV genotype 1b. Ombitasvir/paritaprevir/ritonavir was also recommended as a therapy for HCV genotype 1b. More recently, elbasvir (NS5A inhibitor)/grazoprevir (NS3/4A protease inhibitor) was also recommended as a potent therapy for HCV genotype 1b infection. This agent achieved an SVR12 as high as 96...
September 2017: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/29430221/successful-treatment-of-oral-lichen-planus-with-direct-acting-antiviral-agents-after-liver-transplantation-for-hepatitis-c-virus-associated-hepatocellular-carcinoma
#20
Yumiko Nagao, Kazunori Nakasone, Tatsuji Maeshiro, Nao Nishida, Kanae Kimura, Yuji Kawahigashi, Yasuhito Tanaka, Michio Sata
Hepatitis C virus (HCV) infection is frequently associated with various extrahepatic manifestations, such as autoimmune features and immune complex deposit diseases. Oral lichen planus (OLP) is one such extrahepatic manifestation of HCV infection. Recently, direct-acting antivirals (DAA) have proved to be highly effective and safe for the eradication of HCV. Herein, we report a case of OLP accompanied by HCV-related hepatocellular carcinoma (HCC) that disappeared after liver transplantation and achievement of sustained virological response following interferon (IFN)-free treatment with ledipasvir (LDV) and sofosbuvir (SOF)...
September 2017: Case Reports in Gastroenterology
keyword
keyword
70557
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"